Appeals court overturns ruling in Axonics-Medtronic neurostim patent dispute

Gen­mab is an un­usu­al com­pa­ny in phar­ma. In 25 years, it has 44 INDs — 20 of those are still in clin­i­cal de­vel­op­ment — and

Bio­gen on Wednes­day said that an ex­per­i­men­tal, high­er dose of its spinal mus­cu­lar at­ro­phy drug Spin­raza met the pri­ma­ry end­point of a clin­i­cal tri­al com­par­ing